Inhibitors of RORγ

Information

  • Patent Grant
  • 10913739
  • Patent Number
    10,913,739
  • Date Filed
    Tuesday, July 24, 2018
    6 years ago
  • Date Issued
    Tuesday, February 9, 2021
    3 years ago
Abstract
The present disclosure relates to processes for the production of salts and crystalline forms of a compound having the formula.
Description
BACKGROUND

Retinoic acid receptor-related orphan receptors (RORs) are a subfamily of transcription factors in the steroid hormone nuclear receptor superfamily (Jetten & Joo (2006) Adv. Dev. Biol. 2006, 16, 313-355). The ROR family consists of ROR alpha (RORα), ROR beta (RORβ) and ROR gamma (RORγ), each encoded by a separate gene (in human: RORA, RORB and RORC, respectively; in mouse: rora, rorb and rorc, respectively). RORs contain four principal domains shared by the majority of nuclear receptors: an N-terminal domain, a highly conserved DNA-binding domain (DBD) consisting of two zinc finger motifs, a hinge domain, and a ligand binding domain (LBD). RORγ has two isoforms: RORγ1 and RORγ2 (also known as RORγt). RORγ1 is expressed in a variety of tissues including thymus, muscle, kidney and liver, while RORγt is exclusively expressed in the cells of the immune system. RORγt has a critical role in thymopoiesis and the development of several secondary lymphoid tissues, and is a key regulator of Th17 cell differentiation (Jetten, 2009, Nucl. Recept. Signal., 7:e003, doi:10.1621/nrs.07003, Epub 2009 Apr. 3).


Th17 cells are a subset of T helper cells which preferentially produce the pro-inflammatory cytokines IL-17A, IL-17F, IL-21 and IL-22. Th17 cells and their effector molecules, such as IL-17, IL-21, IL-22, GM-CSF and CCL20, are associated with the pathogenesis of several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, allergy and asthma (Maddur et al., 2012, Am. J. Pathol., 181:8-18). They are also important in the pathogenesis of acne (Thiboutot et al., 2014, J. Invest. Dermatol., 134(2):307-10, doi: 10.1038/jid.2013.400; Agak et al., 2014, J. Invest. Dermatol., 134(2):366-73, doi: 10.1038/jid.2013.334, Epub 2013 Aug. 7), inflammation associated with endometriosis (Hirata et al., 2010, Endocrinol., 151:5468-5476; Hirata et al., 2011, Fertil Steril., July; 96(1):113-7, doi: 10.1016/j.fertnstert.2011.04.060, Epub 2011 May 20), and many other conditions such as multiple sclerosis, rheumatoid arthritis, cancer, metabolic syndrome, obesity hepatosteatosis, insulin resistance, and diabetes (Meissburger et al., 2011, EMBO Mol. Med., 3:637-651; Tosolini et al., 2011, Cancer Res., 71:1263-1271, doi: 10.1158/0008-5472.CAN-10-2907, Epub 2011 Feb. 8; Su et al., 2014, Immunol. Res., 58:118-124, doi: 10.1007/s12026-013-8483-y, Epub 2014 Jan. 9; Carmi et al., 2011, J. Immunol., 186:3462-3471, doi: 10.4049/jimmuno1.1002901, Epub 2011 Feb. 7; Chen et al., 2013, Histopathology, 63:225-233, doi: 10.1111/his.12156, Epub 2013 Jun. 6).


Compound 1 is an inhibitor of RORγ and has therapeutic properties against a number of RORγ mediated diseases. Compound 1 is exemplified in U.S. Pat. No. 9,266,886 and has the formula:




embedded image


Despite its potential for commercialization, Compound 1 is susceptible to oxidation, particularly in solution. This makes it difficult to formulate pharmaceutically acceptable salts and polymorphs which are amendable to large scale manufacturing and formulating. Thus, the need to find alternative manufacturing methods for this potent inhibitor remains.


SUMMARY

A two-step method for the preparation of a bis-hydrogen bromide salt form of Compound 1 was identified. This process involved the formation and isolation of a mono-hydrogen bromide salt of Compound 1 by treatment with hydrobromic acid followed by a second independent treatment step with hydrobromic acid to form a bis-hydrogen bromide salt of Compound 1. This method required the use of HBr and MeOH during the final steps of the synthesis. This transformation led to contamination of the product from production of MeBr. This problem has been solved herein by slurrying the product in a mixture of isopropyl acetate and water. Thus, disclosed herein are methods of removing methyl bromide from a composition comprising methyl bromide and crystalline form D bis-hydrogen bromide salt of Compound 1.


Also provided is a one step process for forming a bis-hydrogen bromide salt form of Compound 1. In this aspect, neutralizing the reductive amination reaction mixture, thereby resulting in precipitation, provided Compound 1 as a free base in high purity and good yield, particularly on a larger scale. For example, reactions were effective at >3 kg scale with 98% yield and in >99 area % purity. See e.g., the Exemplification section. From this, treatment with a sufficient amount of hydrobromic acid afforded the desired bis-hydrogen bromide salt without the need to use MeOH. While no detectable contamination from MeBr was observed, this process led to the formation of a mixture of crystalline forms: Form E, Form F, and Form G. This problem, however, was solved by slurrying the product in a mixture of isopropyl acetate and water to afford a single bis-hydrogen bromide crystal form of Compound 1, i.e., Form D. Thus, in addition to the one-step process, provided herein are methods of converting crystalline Forms E, F and G of a bis-hydrogen bromide salt of Compound 1 to Form D crystalline bis-hydrogen bromide salt of Compound 1.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1. depicts an X-ray powder diffraction pattern (XRPD) for Form D of Compound 1.



FIG. 2. depicts a Differential Scanning calorimetry (DSC) spectrum for Form D of Compound 1.



FIG. 3. depicts a thermal gravimetric analysis (TGA) pattern for Form D of Compound 1.



FIG. 4. depicts a Dynamic Vapor Sorption (DVS) isotherm plot for Form D of Compound 1.



FIG. 5. depicts an X-ray powder diffraction pattern (XRPD) for Form E of Compound 1.



FIG. 6. depicts a Differential Scanning calorimetry (DSC) spectrum for Form E of Compound 1.



FIG. 7. depicts a thermal gravimetric analysis (TGA) pattern for Form E of Compound 1.



FIG. 8. depicts an 1H-NMR spectrum for Compound 1 made by conditions described herein.





DETAILED DESCRIPTION

Provided herein are methods of removing methyl bromide from a composition comprising methyl bromide and a bis-hydrogen bromide salt of Compound 1 (e.g., crystalline Form D of the bis-hydrogen bromide salt of Compound 1) comprising i) slurrying the composition in a mixture of isopropyl acetate/water or a mixture of heptane/water; and ii) separating the bis-hydrogen bromide salt of the compound from the mixture of isopropyl acetate/water or the mixture of heptane/water.


Also provided herein are methods for preparing a free base form of Compound 1, the method comprising i) reductively aminating an aldehyde compound represented by the following structural formula:




embedded image



with an amine compound represented by the following structural formula:




embedded image



wherein the reductive amination is carried out in the presence of ethanol, and in the presence of an imine reducing agent; ii) quenching the reductive amination mixture with acid; iii) neutralizing the resulting solution with base, thereby precipitating the free base form of the compound; and iv) isolating the precipitated free-based form of the compound from the solution. From the free-base, the bis-hydrogen bromide salt can then be prepared directly (i.e., without first isolating the mono-hydrogen bromide salt) by adding sufficient hydrobromic acid to the free-base to form the bis-hydrogen bromide salt in one step.


Further provided herein are methods of converting crystalline Forms E, F and G of a bis-hydrogen bromide salt having the following structural formula:




embedded image



to crystalline Form D bis-hydrogen bromide salt comprising i) slurrying a composition comprising one or more of crystalline Forms E, F, and G in a mixture of isopropyl acetate/water; and ii) separating the crystalline form D bis-hydrogen bromide salt from the mixture of isopropyl acetate/water.


The bis-hydrogen bromide salts formed from the processes described herein have a purity of >95% such as, e.g., >96%, >97%, >98%, >99%, or 99.5% or greater.


I. Definitions


When used alone, the term “Form D” refers to the crystalline polymorph Form D of Compound 1. The terms “Form D”, “Form D of Compound 1”, and “crystalline Form D of Compound 1” are used interchangeably. Similarly, when used alone, the term “Form E” refers to the crystalline polymorph Form E of Compound 1. The terms “Form E”, “Form E of Compound 1”, and “crystalline Form E of Compound 1” are used interchangeably.


The term “amorphous” means a solid that is present in a non-crystalline state or form. Amorphous solids are disordered arrangements of molecules and therefore possess no distinguishable crystal lattice or unit cell and consequently have no definable long range ordering. Solid state ordering of solids may be determined by standard techniques known in the art, e.g., by X-ray powder diffraction (XRPD) or differential scanning calorimetry (DSC). Amorphous solids can also be differentiated from crystalline solids e.g., by birefringence using polarized light microscopy.


“Purity” is expressed in terms of percentage and can be calculated by dividing the mass of the mono- and bis-hydrogen bromide salt forms of Compound 1 by the total mass of the sample, and then multiplying this number by 100. This calculation does not account for solvated forms. Thus, 90% pure or has a purity of 90% means that the designated mono- or bis-hydrogen bromide salt form of Compound 1, or designated polymorphic form makes up 90% by weight of the sample. In one aspect, the purity of the salt and crystalline forms described herein are >90%, >95%, >97%, and >99% pure (e.g., >99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, and 99.9%) by weight. In one aspect, the purity of the salt and crystalline forms described herein are >90%, >95%, >97%, and >99% pure (e.g., >99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, and 99.9%) by weight and free from other salt or polymorphic forms.


When purity is defined in terms of area such as >99% area, it will be understood that this refers to the purity of the identified compound as determined by the HPLC peak area percentage.


The 2-theta values of the X-ray powder diffraction patterns for the crystalline forms described herein may vary slightly from one instrument to another and also depending on variations in sample preparation and batch to batch variation. Therefore, the XRPD patterns/assignments recited herein are not to be construed as absolute and can vary ±0.2 degrees.


“Substantially the same XRPD pattern” means that for comparison purposes, at least 90% of the peaks shown are present. It is to be further understood that for comparison purposes some variability in peak intensities from those shown are allowed, such as ±0.2 degrees.


In one aspect, crystalline Form D of Compound 1 as made by the processes described herein is characterized by at least three, at least four, or at least five x-ray powder diffraction peaks at 2Θ angles selected from 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°. Alternatively, crystalline Form D of Compound 1 is characterized by x-ray powder diffraction peaks at 2Θ angles 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°. In another alternative, crystalline Form D of Compound 1 is characterized by at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty, at least thirty-one, at least thirty-two, at least thirty-three, at least thirty-four, at least thirty-five, or at least thirty-six, x-ray powder diffraction peaks at 2Θ angles selected from Table 1. In another alternative, crystalline Form D of compound 1 is characterized by x-ray powder diffraction peaks at 7.58°, 9.02°, 14.56°, 14.24°, 15.24°, 15.90°, 17.16°, 18.54°, 18.82°, 20.14°, and 22.46°. In another alternative, crystalline Form D of compound 1 is characterized by x-ray powder diffraction peaks at 7.58°, 9.02°, 14.56°, 14.24°, 15.24°, 15.90°, 17.16°, 18.54°, 18.82°,20.14°, 22.46°, 20.70°, 21.02°, 21.70°, 24.36°, and 24.58°. In another alternative, crystalline Form D of compound 1 is characterized by x-ray powder diffraction peaks at 7.58°, 9.02°, 14.56°, 14.24°, 15.24°, 15.90°, 17.16°, 18.54°, 18.82°,20.14°, 22.46°, 20.70°, 21.02°, 21.70°, 24.36°, 24.58°, 25.66°, 25.82°, 26.51°, 26.82°, 29.68°, and 33.70°. In another alternative, crystalline Form D of Compound 1 is characterized by x-ray powder diffraction peaks in Table 1. In another aspect, crystalline Form D of Compound 1 has an XRPD pattern that is substantially the same XRPD pattern shown in FIG. 1. In another aspect, crystalline Form D of Compound 1 has a DSC pattern that is substantially the same DSC pattern shown in FIG. 2. In another aspect, crystalline Form D of Compound 1 has a TGA pattern that is substantially the same TGA pattern shown in FIG. 3. In one aspect, the crystalline Form D of Compound 1 is a bis-hydrogen bromide salt having one or more of the XRPD peaks defined above. In one aspect, Form D of Compound 1 is a hydrate (e.g., a dihydrate) having one or more of the XRPD peaks defined above. In another aspect, Form D of Compound 1 is a bis-hydrogen bromide salt that is a dihydrate and has one or more of the XRPD peaks defined above.









TABLE 1







Form D












2-






Theta
d(A)
Height
I %
















7.579
11.655
45
36



9.02
9.7963
64
51.2



13.403
6.6006
15
12



14.24
6.2147
85
68



14.562
6.0778
31
24.8



15.241
5.8087
125
100



15.9
5.5692
103
82.4



16.8
5.2729
22
17.6



17.162
5.1624
44
35.2



17.342
5.1092
26
20.8



18.54
4.7817
55
44



18.818
4.7117
53
42.4



19.279
4.6001
13
10.4



19.643
4.5157
20
16



20.14
4.4054
48
38.4



20.7
4.2873
49
39.2



21.02
4.2229
42
33.6



21.699
4.0921
49
39.2



22.46
3.9553
88
70.4



23.362
3.8045
24
19.2



23.698
3.7513
17
13.6



24.362
3.6505
41
32.8



24.578
3.619
29
23.2



24.799
3.5873
11
8.8



25.237
3.526
35
28



25.406
3.503
18
14.4



25.659
3.4689
42
33.6



25.822
3.4474
59
47.2



26.102
3.411
25
20



26.506
3.36
27
21.6



26.82
3.3213
67
53.6



27.122
3.285
19
15.2



27.562
3.2336
10
8



28.004
3.1835
19
15.2



28.604
3.1182
20
16



29.679
3.0076
35
28



33.701
2.6573
48
38.4










In one aspect, crystalline Form E formed by the one-step process described herein is characterized by at least three, at least four, or at least five x-ray powder diffraction peaks at 2Θ angles selected from 4.1°, 8.3°, 12.70°, 16.64°, 16.98°, and 21.32°. Alternatively, crystalline Form E of Compound 1 is characterized by x-ray powder diffraction peaks at 2Θ angles 4.1°, 8.3°, 12.70°, 16.64°, 16.98°, and 21.32°. In another alternative, crystalline Form E of Compound 1 is characterized by at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, at least twenty-eight, at least twenty-nine, at least thirty, at least thirty-one, at least thirty-two, at least thirty-three, at least thirty-four, at least thirty-five, or at least thirty-six x-ray powder diffraction peaks at 2Θ angles selected from Table 2. In another alternative, crystalline Form E of Compound 1 is characterized by x-ray powder diffraction peaks in Table 2. In another aspect, crystalline Form E of Compound 1 has an XRPD pattern that is substantially the same XRPD pattern shown in FIG. 5. In another aspect, crystalline Form E of Compound 1 has a DSC pattern that is substantially the same DSC pattern shown in FIG. 6. In another aspect, crystalline Form E of Compound 1 has a TGA pattern that is substantially the same TGA pattern shown in FIG. 7. In one aspect, the crystalline Form E of Compound 1 is a bis-hydrogen bromide salt having one or more of the XRPD peaks defined above.









TABLE 2







Form E












2-






Theta
d(A)
Height
I %
















4.1
21.5348
75
41



5.662
15.5969
17
9.3



5.801
15.2235
16
8.7



8.3
10.6434
157
85.8



11.781
7.5054
15
8.2



12.659
6.9866
183
100



14.008
6.3168
13
7.1



14.241
6.214
12
6.6



14.403
6.1446
13
7.1



14.677
6.0305
11
6



15.7
5.6398
16
8.7



16.34
5.4203
5
2.7



16.644
5.3219
26
14.2



16.98
5.2174
84
45.9



17.523
5.0569
12
6.6



18.388
4.8209
10
5.5



19.015
4.6635
9
4.9



19.16
4.6284
6
3.3



19.44
4.5624
5
2.7



20.02
4.4315
7
3.8



20.579
4.3123
17
9.3



21.323
4.1636
40
21.9



21.68
4.0957
30
16.4



21.9
4.0551
16
8.7



22.487
3.9506
10
5.5



22.914
3.8779
10
5.5



23.685
3.7535
11
6



24.18
3.6777
8
4.4



24.419
3.6422
22
12



24.779
3.5901
31
16.9



24.779
3.5901
31
16.9



25.72
3.4609
20
10.9



26.499
3.3608
10
5.5



27.041
3.2947
14
7.7



27.204
3.2753
17
9.3



28.14
3.1685
6
3.3



28.604
3.1181
13
7.1











2. General Preparation Methods


Provided herein are processes for preparing mono- and bis-hydrogen bromide salts of Compound 1. Starting materials and synthetic methods for preparing Compound 1 and precursor materials can be found in e.g., General Procedure B of U.S. Pat. No. 9,266,886, the contents of which are incorporated herein by reference.


A two-step process was initially developed to form the bis-hydrogen bromide salt of Compound 1. See e.g., Scheme 5 in the Exemplification section, a portion of which is depicted here as Scheme 1. This process comprised first forming and isolating a mono-hydrogen bromide salt of Compound 1 followed by conversion of the mono-hydrogen bromide salt to the bis-hydrogen bromide salt of Compound 1.




embedded image


While this process initially proved useful in forming the desired product, the combination of HBr and MeOH resulted in product contamination, i.e., excess methyl bromide was present in the initially isolated product. It was not until after significant efforts, that slurrying the product in a mixture of isopropyl acetate and water was found to effectively remove the excess methyl bromide. Although a mixture of heptane and water was also found to be effective, the solubility of the bis-hydrogen bromide crystalline Form D salt was greater in the isopropyl acetate/water mixture, and therefore this mixture was chosen for scale up purposes. A schematic representation of this process is shown below as Scheme 2.




embedded image


Provided herein, therefore is a method of removing methyl bromide from a composition comprising methyl bromide and a bis-hydrogen bromide salt of Compound 1 (e.g., crystalline Form D of the bis-hydrogen bromide salt of Compound 1) comprising i) slurrying the composition in a mixture of isopropyl acetate/water or a mixture of heptane/water; and ii) separating the bis-hydrogen bromide salt of the compound from the mixture of isopropyl acetate/water or the mixture of heptane/water.


In one aspect, removing methyl bromide from a composition comprising methyl bromide and a bis-hydrogen bromide salt of Compound 1 comprises slurrying the composition in a mixture of isopropyl acetate comprising 0.25% to 2.5% v/v of water; and ii) separating the bis-hydrogen bromide salt of the compound from the mixture of isopropyl acetate/water. In one aspect, the mixture comprises isopropyl acetate comprising 0.5% to 2.0% v/v of water, 0.7% to 1.7% v/v of water, 0.8% to 1.5% v/v of water, 0.9% to 1.3% v/v of water, 0.9% to 1.1% v/v of water, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.


In some aspects, prior to slurrying the composition, the methyl bromide present in the composition is greater than 45 ppm, greater than 50 ppm, greater than 55 ppm, or greater than 60 ppm. For example, the amount of methyl bromide present in the composition may be from 50 ppm to 1000 ppm. The amounts of methyl bromide present in the composition prior to slurrying refers to the amount present in a dried composition, e.g., prior to slurrying the composition is dried (e.g., at approximately 15 to 50° C. such as 20 to 25° C.) under approximately −0.096 MPa vacuum for 20 hours or more. In a further aspect, prior to slurrying the composition, the methyl bromide present in the composition is greater than 45 ppm, greater than 50 ppm, greater than 55 ppm, greater than 60 ppm, or from 50 ppm to 1000 ppm; and the mixture comprises isopropyl acetate comprising 0.5% to 2.0% v/v of water, 0.7% to 1.7% v/v of water, 0.8% to 1.5% v/v of water, 0.9% to 1.3% v/v of water, 0.9% to 1.1% v/v of water, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.


In some aspects, separating the crystalline form D bis-hydrogen bromide salt from the mixture results in a crystalline form D bis-hydrogen bromide salt having less than 45 ppm of methyl bromide present. For example, in certain instances, separating the crystalline form D bis-hydrogen bromide salt from the mixture results in a crystalline form D bis-hydrogen bromide salt having is less than 40 ppm, less than 30 ppm, less than 20 ppm, less than 10 ppm, less than 5 ppm, or less than 1 ppm of methyl bromide present. In one aspect, separating the crystalline form D bis-hydrogen bromide salt from the mixture results in a crystalline form D bis-hydrogen bromide salt having an amount of methyl bromide present that is below the level of detection.


In some aspects, separating the crystalline form D bis-hydrogen bromide salt from the mixture results in a crystalline form D bis-hydrogen bromide salt having less than 45 ppm, less than 40 ppm, less than 30 ppm, less than 20 ppm, less than 10 ppm, less than 5 ppm, or less than 1 ppm of methyl bromide present, or an amount of methyl bromide that is below the level of detection; and wherein prior to slurrying the composition, the methyl bromide present in the composition is greater than 45 ppm, greater than 50 ppm, greater than 55 ppm, greater than 60 ppm, or from 50 ppm to 1000 ppm. In some aspects, separating the crystalline form D bis-hydrogen bromide salt from the mixture results in a crystalline form D bis-hydrogen bromide salt having less than 45 ppm, less than 40 ppm, less than 30 ppm, less than 20 ppm, less than 10 ppm, less than 5 ppm, or less than 1 ppm of methyl bromide present, or an amount of methyl bromide that is below the level of detection; wherein prior to slurrying the composition, the methyl bromide present in the composition is greater than 45 ppm, greater than 50 ppm, greater than 55 ppm, greater than 60 ppm, or from 50 ppm to 1000 ppm; and wherein the mixture comprises isopropyl acetate comprising 0.5% to 2.0% v/v of water, 0.7% to 1.7% v/v of water, 0.8% to 1.5% v/v of water, 0.9% to 1.3% v/v of water, 0.9% to 1.1% v/v of water, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.


Also provided is a one-step method for preparing bis-hydrogen bromide salt of Compound 1 was also identified. In this instance, it was found that switching the solvent from CH2Cl2 to EtOH in the reductive amination reaction followed by neutralizing the reductive amination mixture, and precipitating the resulting free base afforded a highly purified free-base product, or at least in pure enough form such that it could be directly converted to the bis-hydrogen bromide salt without the separate step of isolating the mono-hydrogen bromide salt. This method is depicted in Scheme 6 below, a portion of which is represented here as Scheme 3.




embedded image


Thus, in one aspect, provided herein are alternative methods for preparing a free base form of Compound 1, the method comprising i) reductively aminating an aldehyde compound represented by the following structural formula:




embedded image



with an amine compound represented by the following structural formula:




embedded image



wherein the reductive amination is carried out in the presence of ethanol, and in the presence of an imine reducing agent; ii) quenching the reductive amination mixture with acid; iii) neutralizing the resulting solution with base, thereby precipitating the free base form of the compound; and iv) isolating the precipitated free-based form of the compound from the solution. In one aspect, a solution of the aldehyde compound in isopropyl acetate is added to a slurry of the imine reducing agent in a solution of the trialkyl amine and the amine compound in ethanol. In one aspect, the acid used for quenching is hydrochloric acid. In one aspect, the base used is an aqueous base such as a solution of aqueous sodium hydroxide. In one aspect, the solution is neutralized in step iii) to pH 5 to 7. In one aspect, the amine compound is formed in situ from treating an acid salt form (e.g., a hydrochloric acid salt such as a di-hydrochloric acid salt) of the amine with a tertiary amine base


Again, tertiary amines for performing reductive aminations are known and include, but are not limited to, trialkylamines such as diisopropylethylamine (DIPEA or iPr2NEt) and trimethylamine (TEA). See e.g., March's Advanced Organic Chemistry, fifth edition, John Wiley & Sons 2001. In one instance, the amine used is DIPEA.


Again, reducing agents for performing reductive aminations are known and include, but are not limited to, sodium triacetoxyborohydride (NaBH(OAc)3), sodium borohydride (NaBH4), palladium on carbon with H2, and platinum on carbon with H2. See e.g., March's Advanced Organic Chemistry, fifth edition, John Wiley & Sons 2001. In one instance, the reducing agent is NaBH(OAc)3.


From the free-base, the bis-hydrogen bromide salt can then be prepared directly (i.e., without first isolating the mono-hydrogen bromide salt) by adding sufficient hydrobromic acid to the free-base to form the bis-hydrogen bromide salt. In one aspect, formation of the bis-hydrogen bromide salt from the free-based further comprises the addition of a mixture of isopropanol, MTBE, and acetic acid. In another aspect, formation of the bis-hydrogen bromide salt from the free-based further comprises the addition of a mixture of acetic acid and MEK.


Here, the amount and concentration of hydrobromic acid that is sufficient to form the bis-hydrogen bromide salt can vary, but is typically from 2 to 5 equivalents of, for example, 35% to 55% hydrobromic acid, 37% to 53% hydrobromic acid, or 40% to 48% hydrobromic acid. In one aspect, 40% or 48% hydrobromic acid is used. In one aspect, 2 to 4 equivalents, 2 to 3 equivalents, 2 to 2.5 equivalents or 2.1 equivalents of 40% or 48% hydrobromic acid is used.


Although the need to isolate the mono-hydrogen bromide salt first prior to forming the bis-hydrogen bromide salt was eliminated with this one-step method, and contamination of product from methyl bromide was absent because of the avoidance of MeOH, the initial bis-hydrogen bromide salt formed was determined to be existed as a mixture of crystalline Forms E, F, and G. Forms F and G were not characterized further. To overcome this problem, it was found that slurrying the mixture of crystalline forms in isopropyl acetate/water resulted in the formation of single crystalline Form D bis-hydrogen bromide salt. See e.g., Scheme 4 below.




embedded image


Thus, in one aspect, provided herein is a method of converting crystalline Forms E, F and G of the bis-hydrogen bromide salt of Compound 1 to crystalline Form D bis-hydrogen bromide salt, comprising i) slurrying a composition comprising one or more of crystalline forms E, F and G in a mixture of isopropyl acetate/water containing between 0.25%-2.5% v/v; and ii) separating (e.g., via filtration) the crystalline form D of the bis-hydrogen bromide salt of the compound from the mixture of isopropyl acetate/water.


In one aspect, the mixture comprises isopropyl acetate comprising 0.5% to 2.0% v/v of water, 0.7% to 1.7% v/v of water, 0.8% to 1.5% v/v of water, 0.9% to 1.3% v/v of water, 0.9% to 1.1% v/v of water, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.


In one aspect, the amount of Form E, F, and G present in the composition is greater than 90% by weight, such as greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, or greater than 98%, greater than 99%.


EXEMPLIFICATION

The following non-limiting examples are provided to further illustrate the present disclosure.


Materials/Methods


Differential Scanning Calorimetry (DSC)


DSC was performed using a TA Instruments 2920 differential scanning calorimeter. Temperature calibration was performed using NIST-traceable indium metal. The sample was placed into an aluminum Tzero crimped pan (T0C) and the weight was accurately recorded. A weighed aluminum pan configured as the sample pan was placed on the reference side of the cell. The data acquisition parameters and pan configuration for each thermogram are displayed in the image in the figure. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., (−30)-250-10 means “from −30° C. to 250° C., at 10° C./min”.


Thermal Gravimetric Analysis (TG)


TG analyses were performed using a TA Instruments Q5000 IR thermogravimetric analyzer. Temperature calibration was performed using nickel and Alumel™. Each sample was placed in a platinum pan. The sample was hermetically sealed, the lid pierced, then inserted into the TG furnace. The furnace was heated under nitrogen. The data acquisition parameters for each thermogram are displayed in the in the figure. The method code on the thermogram is an abbreviation for the start and end temperature as well as the heating rate; e.g., 00-350-10 means “from ambient ° C. to 350° C., at 10° C./min”.


X-Ray Powder Diffraction (XRPD)


XRPD patterns were collected with a PANalytical X'Pert PRO MPD diffractometer using an incident beam of Cu radiation produced using an Optix long, fine-focus source. An elliptically graded multilayer mirror was used to focus Cu Kα X-rays through the specimen and onto the detector. Prior to the analysis, a silicon specimen (NIST SRM 640e) was analyzed to verify the observed position of the Si 111 peak is consistent with the NIST-certified position. A specimen of the sample was sandwiched between 3-μm-thick films and analyzed in transmission geometry. A beam-stop, short antiscatter extension, antiscatter knife edge were used to minimize the background generated by air. Soller slits for the incident and diffracted beams were used to minimize broadening from axial divergence. Diffraction patterns were collected using a scanning position-sensitive detector (X'Celerator) located 240 mm from the specimen and Data Collector software v. 2.2b. The data acquisition parameters for each pattern are displayed above the image in the Data section of this report including the divergence slit (DS) before the mirror.


Formation and Analysis of Salt Forms


Two-Step Formation


The two-step formation to arrive at Form D is shown below in Scheme 5. Intermediate 2 was prepared according to general procedure B in U.S. Pat. No. 9,266,886, the contents of which are incorporated herein by reference.




embedded image


Intermediate 2 is suspended in dichloromethane and the amine liberated by treatment with diisopropylethylamine. The solution is cooled to −50° C. and subsequently treated with NaBH(OAc)3 and the aldehyde. After the reductive amination reaction is complete, the bis-hydrogen bromide is isolated by the following sequence of operations. The dichloromethane solution of 3 is acidified with acetic acid, treated with active carbon and filtered. The solvent is switched to isopropanol. Addition of 40% aqueous HBr (1.4 equivalents), cooling to 10-15° C., seeding and continued aging affords the mono-HBr salt. This material was isolated by centrifugation and dried at 30-45° C. in vacuum. The mono-HBr salt is then converted to the bis-HBr salt by dissolving the mono salt in methanol, adding 1.1 equiv of 40% aqueous HBr, then seeding, followed by additions of MTBE and water. The bis-HBr salt is isolated by filtration and drying at 30-45° C. in vacuum. The final product is isolated as the bis-hydrogen bromide salt Form D with contamination from MeBr (approximately 40 ppm or more at laboratory scale and approximately 227 ppm or greater on plant production of 100 grams or greater).


After numerous attempts and various conditions, it was found that slurrying the bis-hydrogen bromide salt Form D from isopropyl acetate containing 1% water at room temperature effectively produced bis-hydrogen bromide salt Form D in high purity. A combination of heptane and water also removed the methyl bromide, but this combination was not pursued further. A summary of the experiments leading up to these conclusions is provided below.


Based on previous research, residual MeBr could be removed effectively by re-crystallizing from MeOH/MTBE/H2O=1.75 V/12 V/0.15 V. However, considering the potential risk which MeOH may react with HBr contained in Compound 1, MTBE was tried as only re-slurry solvent. Two reactions were carried out under different N2 atmosphere: Stirring at approximately 30 to 35° C. for 96 h, residual MeBr was 65 ppm and 40 ppm respectively. See Table 3. After re-slurry with 20 V of MTBE at approximately 30 to 35° C. for 116 h, residual MeBr in both reactions was decreased to less than 50 ppm.














TABLE 3







Residual







MeBr
Br


Scale
Conditions
(ppm)
content
Yield
Note







40 g
Re-slurry with
164 (48 h) 
21.1%
94.1%
Residual



20 V MTBE at
65 (96 h) 
(Corrected

MeOH:



30~35° C. and
34 (114 h)
by KF)

0.07%



stir
17 (140 h)


MTBE:



with 180 rpm.



0.23%



Adjust to



20~25° C.



Filter, and dry



N2 balloon



always


40 g
Re-slurry with
180 (48 h) 
21.4%
93.8%
Residual



20 V MTBE at
40 (96 h) 
(Corrected

MeOH:



30~35° C. and
20 (116 h)
by KF)

0.12%



stir with
N.D (140 h)


MTBE:



180 rpm.



0.11%



Adjust to



20-25° C.



Filter, and dry.



N2 flow after



48 h









The developed purification process was then executed in pilot plant study but failed as the residual MeBr was 227 ppm (limitation: Residual MeBr≤40 ppm). Because of this, other solvents (DCM, IPAc, and n-heptane) were tried. After investigation, it was found that DCM was not a good choice because the crystal form changed, whereas the crystal form remained consistent with Form D after stirring at approximately 20 to 30° C. for 3 days in IPAc or n-heptane. So studies about how to remove residual MeBr were carried out in IPAc and n-heptane. See Table 4. The effect of removing MeBr was no different after stirring for 23 h (n-heptane: 148 ppm; IPAc: 153 ppm). However, since the solubility of the bis-hydrogen bromide salt Form D was slightly higher than that in n-heptane, IPAc was chosen as the re-slurry solvent. NMR data for bis-hydrogen bromide crystalline Form D of Compound 1 is as follows: 1H NMR (500 MHz, CD3OD): δ 9.12 (s, 1H), 9.11 (s, 1H), 8.57 (d, J=8.5 Hz, 1H), 8.37 (s, 1H), 7.97 (d, J=8.5 Hz, 1H), 5.22 (d, J=16 Hz, 1H), 4.89 (d, J=4.0 Hz, 1H), 4.85 (s, 2H), 4.77 (d, J=17.5 Hz, 1H), 3.42 (m, 2H), 3.37 (q, J=7.5 Hz, 2H), 2.54 (m, 1H), 2.17 (m, 1H), 2.04 (m, 5H), 1.45 (m, 2H), 1.33 (d, J=7.0 Hz, 3H), 1.28 (t, J=7.5 Hz, 3H), 1.23 (m, 2H), 1.11 (d, J=6.5 Hz, 3H).











TABLE 4









Residual MeBr











Scale
Conditions
Time
Wet cake
Dried cake





7 g
Re-slurry 7 g with 10 V
3 h
117
201



IPAc at 20~25° C. under
6 h
140
216



nitrogen balloon
23 h 
121
153


7 g
Re-slurry 7 g with 10 V
3 h
120
201



n-heptane at 20~25° C.
6 h
115
227



under nitrogen balloon
23 h 
110
148









To study the influence on the amount of water for the IPAc/water mixture, reactions with different content of water in IPAc were carried out (0.25%, 0.5%, 1.0%, 2.0%). It was found water could improve the efficiency of removing MeBr and that best results were obtained when 1.0% water was used (Table 5, Entry 3; residual MeBr was less than 40 ppm after stirred for 6 h). XRPD was consistent.















TABLE 5











Residual MeBr
Br







(ppm)
content



















Wet
Dried
corrected



Entry
Scale
Conditions
Time
cake
cake
by KF
Note

















1
10 g
Re-slurry 10
 3 h
102
91
20.95%
Residual




g with 5 V
 6 h
44
66
KF:
MeOH:




IPAc
23 h
<40
<40
5.5%
N.D




containing




IPAc:




0.25% water




0.025%




at 20~25° C.









with 150









rpm







2
10 g
Re-slurry 10
 3 h
87
66
21.88%
Residual




g of S with
 6 h
<40
51
KF:
MeOH:




5 V IPAc
23 h
ND
ND
5.85%
N.D




containing




IPAc:




0.5% water




0.029%




at 20~25° C.









with 150









rpm







3
10 g
Re-slurry 10
 3 h
<40
42
21.88%
Residual




g of S with
 6 h
<40
<40
KF:
MeOH:




5 V IPAc
23 h
ND
ND
5.86%
N.D




containing




IPAc:




1% water at




0.045%




20~25° C.









with 150









rpm







4
10 g
Re-slurry 10
 3 h
42
64
22.34%
Residual




g of S with
 6 h
<40
<40
KF:
MeOH:




5 V IPAc
23 h
67
ND
5.99%
N.D




containing




IPAc:




2% water at




0.016%




20~25° C.









with 150









rpm









With the excess methyl bromide problem solved, another drawback to the two-step process was solved. That is, the two-step process also employed methylene chloride as the solvent for the reductive amination procedure. On large manufacturing scale, this would require strict controls due to air and water quality regulations. To overcome these obstacles, a one-step approach to obtain the bis-hydrogen bromide salt Form D directly from the free base of Compound 1 was realized.


One-Step Formation


The one-step approach is shown below in Scheme 6. Intermediate 2 was again prepared according to general procedure B in U.S. Pat. No. 9,266,886.




embedded image


A typical reaction can proceed as follows. To the 30-gal reactor was added 2 (5.12 kg, 9.2 mol, 1.0 equiv). In a carboy was charged ethanol (27.3 L, 7 vol relative to sodium triacetoxyborohydride (STAB)) and DIPEA (3.57 kg, 27.6 mol, 3 equiv relative to 2). The solution of DIPEA/EtOH was added to the reactor with the 2 with no stirring. A cloud of amine hydrochloride formed in the reactor making it difficult to see the slurry, so the batch was allowed to sit without stirring until this cloud dissipated. After 35 min, the cloud dissipated and the mixture was gently stirred. In an hour, the solids had dissolved. The batch was stirred gently overnight at 10° C. and then the 2 was drained from the reactor into a carboy.


The reactor was charged with STAB (3.91 kg, 18.4 mol, 2 equiv) and pre-made solution of DIPEA (2.383 kg, 18.4 mol, 2 equiv) and ethanol (27.2 L, 7 vol relative to STAB) with the jacket at −5° C. The mixture was allowed to cool to 0° C. over 20 min. The solution of 2 in DIPEA/EtOH was added over 27 min followed by the free aldehyde solution in IPAc over 45 min. The maximum temperature during the aldehyde addition was 3.7° C. The mixture was stirred for 1 h and was sampled for reaction completion.


The reaction was quenched by the addition of 1 N HCl (31.2 L, 8 vol relative to STAB) over 33 min. The temperature rose to 11° C. during this addition. The solids dissolved during this quench and the solution was stirred 1 h. The quenched reaction was transferred to a 100-gal. Pfaudler, glass-lined reactor with the jacket set to 10° C. To the 100-gal reactor was charged 1 N NaOH solution (31.2 L, 8 vol relative to STAB). After this addition, the pH rose from approximately 5 to approximately 6 and solids precipitated. The free base slurry was allowed to stir overnight at approximately 10° C. for convenience. The batch was then transferred to a pressure filter equipped with a tight weave cloth. The initial filtration was performed with occasional stirring and the batch de-liquored in about 4 h. The reactor and filter cake were washed with DI water (2×16 L) and 1:1 ethanol/DI water (16 L). The washes took approximately 30 min each. The wet cake was conditioned for 2 h under 8 psig of nitrogen and then was dried at a jacket temperature 35° C. The drying was monitored by KF analysis. The wet cake contained 21% water and the dried cake before off-loading was 5.4% water. The yield was 4.97 kg (98%). The HPLC analysis of the product was 99.7 area %. The NMR weight assay was 90.8 wt % (FIG. 8) and the final KF analysis was 4.7% water. Residue-on-ignition (ROI) analysis of the free base indicated it had 0.2% residual inorganic material.


The material can then be converted to the bis-hydrogen bromide salt by e.g., contacting the free base (0.8026 g) with acetic acid (2 vol, 1.6052 ml) and stirring the mixture at 250 RPM, heated 30° C. A 48% HBr solution is then added (0.3438 ml, 2.1 equiv) drop wise over 9 min. MEK (4.816 ml, 6 vol) is then added over 50 minutes and the reaction is seeded with bis-hydrogen bromide salt Form D. MEK (8.000 ml, 10 vol) is added at 2 ml slowly added every 5 min. The mixture is then chilled to 5° C. over 1 hour, filtered, rinsed w/MEK (2×3.21 ml), and dried in 40° C. vacuum oven/21 hrs to afford a mixture of bis-hydrogen bromide crystalline salt Forms E, F, and G. This procedure was also completed on a 2.5 kg scale. These forms were not characterized further. It should be noted that a mixture of acetic acid/MEK (or acetic acid/acetone) prevents the product from oiling out as well as the production of MeBr. To obtain a single crystalline form, the mixture of forms were slurried in isopropyl acetate with 1% water which gave the bis-hydrogen bromide salt Form D with 98% yield and in >99 area % purity.


While have described a number of embodiments of this, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this disclosure. Therefore, it will be appreciated that the scope of this disclosure is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.


The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one with ordinary skill in the art.

Claims
  • 1. A method of converting crystalline Forms E, F, and G of a bis-hydrogen bromide salt having the following structural formula:
  • 2. The method of claim 1, wherein the composition is slurried in a mixture of isopropyl acetate comprising 0.25% to 2.5% v/v of water.
  • 3. The method of claim 1, wherein the separation is done by filtration.
  • 4. The method of claim 1, wherein the amount of the one or more crystalline Forms E, F, and G present in the composition is greater than 90% by weight.
  • 5. The method of claim 1, wherein the bis-hydrogen bromide salt is of crystalline Form D characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°.
  • 6. The method of claim 1, wherein the bis-hydrogen bromide salt is of crystalline Form D characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 14.24°, 15.24°, 15.90°, 18.54°, 18.82°, and 22.46°.
RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 national stage filing of International Application No. PCT/US2018/043451, filed Jul. 24, 2018, which claims the benefit of priority to U.S. Provisional Application No. 62/536,114, filed Jul. 24, 2017, the entire contents of each of which are incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2018/043451 7/24/2018 WO 00
Publishing Document Publishing Date Country Kind
WO2019/023207 1/31/2019 WO A
US Referenced Citations (76)
Number Name Date Kind
5238950 Clader et al. Aug 1993 A
5272158 Hartman et al. Dec 1993 A
5326760 McElroy et al. Jul 1994 A
5364869 De Nov 1994 A
5389631 Claremon et al. Feb 1995 A
5571774 Hamprecht et al. Nov 1996 A
5719144 Hartman et al. Feb 1998 A
5770590 Natsugari et al. Jun 1998 A
5786352 Natsugari et al. Jul 1998 A
5959116 Hamprecht et al. Sep 1999 A
6103659 Pasenok et al. Aug 2000 A
6166219 Yamasaki et al. Dec 2000 A
6177443 Madsen et al. Jan 2001 B1
6348032 Sperl et al. Feb 2002 B1
6358978 Ritzeler et al. Mar 2002 B1
6417207 Garvey et al. Jul 2002 B1
6444617 Takaishi et al. Sep 2002 B1
6489315 Natsugari et al. Dec 2002 B1
6512117 Harclerode et al. Jan 2003 B1
6770666 Hashimoto et al. Aug 2004 B2
7112600 Hashimoto et al. Sep 2006 B1
7115752 Lesieur et al. Oct 2006 B2
7183318 Lesieur et al. Feb 2007 B2
7244730 Suzuki et al. Jul 2007 B2
7732616 Marlow et al. Jun 2010 B2
7750021 Mi et al. Jul 2010 B2
8389739 Thacher et al. Mar 2013 B1
8399477 Alisi et al. Mar 2013 B2
8415351 Wagner et al. Apr 2013 B2
9266886 Lotesta et al. Feb 2016 B2
9481674 Claremon et al. Nov 2016 B1
9624217 Claremon et al. Apr 2017 B2
9663515 Claremon et al. May 2017 B2
9796710 Claremon et al. Oct 2017 B2
9868748 Claremon et al. Jan 2018 B2
10047085 Claremon et al. Aug 2018 B2
10087184 Claremon et al. Oct 2018 B2
10301261 Claremon et al. May 2019 B2
10399976 Claremon et al. Sep 2019 B2
20020132817 Natsugari et al. Sep 2002 A1
20030050320 Hashimoto et al. Mar 2003 A1
20040002424 Minn et al. Jan 2004 A1
20040038973 Nahra et al. Feb 2004 A1
20050004204 Suzuki et al. Jan 2005 A1
20050020593 Mailliet et al. Jan 2005 A1
20050234065 Hulin et al. Oct 2005 A1
20060135557 Nan et al. Jun 2006 A1
20070032497 Hashimoto et al. Feb 2007 A1
20070112038 Marlow et al. May 2007 A1
20070258887 Tamagnan et al. Nov 2007 A1
20080277622 Deshpande et al. Nov 2008 A1
20080287462 Chessari et al. Nov 2008 A1
20090036423 Pan et al. Feb 2009 A1
20090076275 Bolin et al. Mar 2009 A1
20090233945 Chessari et al. Sep 2009 A9
20090258871 Jitsuoka et al. Oct 2009 A1
20090270405 Cook, II et al. Oct 2009 A1
20100099684 Cook, II et al. Apr 2010 A1
20110070193 Wagner et al. Mar 2011 A1
20110189167 Flynn et al. Aug 2011 A1
20110313003 Shi et al. Dec 2011 A1
20120077840 Turner et al. Mar 2012 A1
20120115903 Frank et al. May 2012 A1
20120245163 Gomtsyan et al. Sep 2012 A1
20120322837 Maeba et al. Dec 2012 A1
20130143870 Grauert et al. Jun 2013 A1
20130150347 Rudolf et al. Jun 2013 A1
20140163001 Yamamoto et al. Jun 2014 A1
20140228409 Yamamoto et al. Aug 2014 A1
20190322687 Claremon et al. Oct 2019 A1
20190352286 Claremon et al. Nov 2019 A1
20200062707 Claremon et al. Feb 2020 A1
20200079767 Claremon et al. Mar 2020 A1
20200148677 Duguid et al. May 2020 A1
20200165245 Deng et al. May 2020 A1
20200172535 Claremon et al. Jun 2020 A1
Foreign Referenced Citations (234)
Number Date Country
2031684 Jun 1991 CA
2134192 May 1995 CA
2352612 Jun 2000 CA
2524027 Dec 2004 CA
1424770 Jun 2003 CN
1869036 Nov 2006 CN
101225070 Jul 2008 CN
101455661 Jun 2009 CN
102180780 Sep 2011 CN
104024239 Sep 2014 CN
4343922 Jun 1995 DE
4446396 Jul 1995 DE
254951 Feb 1988 EP
321368 Jun 1989 EP
468187 Jan 1992 EP
520277 Dec 1992 EP
520573 Dec 1992 EP
540334 May 1993 EP
655439 May 1995 EP
733632 Sep 1996 EP
1178048 Feb 2002 EP
2327704 Jun 2011 EP
2725946 Apr 1996 FR
2926554 Jul 2009 FR
2276384 Sep 1994 GB
H06-236056 Aug 1994 JP
H11-43489 Feb 1999 JP
2000-007661 Jan 2000 JP
2003-171380 Jun 2003 JP
2003-531894 Oct 2003 JP
2004-203791 Jul 2004 JP
2015-124178 Jul 2015 JP
WO-199009787 Sep 1990 WO
WO-199400119 Jan 1994 WO
WO-199424712 Oct 1994 WO
WO-199511680 May 1995 WO
WO-199517397 Jun 1995 WO
WO-199626187 Aug 1996 WO
WO-199732832 Sep 1997 WO
WO-199840385 Sep 1998 WO
WO-199842666 Oct 1998 WO
WO-199947132 Sep 1999 WO
WO-199958495 Nov 1999 WO
WO-199958496 Nov 1999 WO
WO-2000032192 Jun 2000 WO
WO-2000067754 Nov 2000 WO
WO-2001005790 Jan 2001 WO
WO-200109076 Feb 2001 WO
WO-2001047883 Jul 2001 WO
WO-2001051128 Jul 2001 WO
WO-200183438 Nov 2001 WO
WO-2001083445 Nov 2001 WO
WO-200185722 Nov 2001 WO
WO-2002024650 Mar 2002 WO
WO-200238107 May 2002 WO
WO-2002081443 Oct 2002 WO
WO-2002081447 Oct 2002 WO
WO-2002081463 Oct 2002 WO
WO-2002085855 Oct 2002 WO
WO-2002094833 Nov 2002 WO
WO-2003008421 Jan 2003 WO
WO-2003029252 Apr 2003 WO
WO-2003029254 Apr 2003 WO
WO-2003043991 May 2003 WO
WO-2003062241 Jul 2003 WO
WO-2003066055 Aug 2003 WO
WO-2003070710 Aug 2003 WO
WO-2003076440 Sep 2003 WO
WO-2003104216 Dec 2003 WO
WO-2004014365 Feb 2004 WO
WO-2004026871 Apr 2004 WO
WO-2004042029 May 2004 WO
WO-2004065351 Aug 2004 WO
WO-2004089897 Oct 2004 WO
WO-2004103309 Dec 2004 WO
WO-2004108133 Dec 2004 WO
WO-2004111010 Dec 2004 WO
WO-2004113330 Dec 2004 WO
WO-2005005392 Jan 2005 WO
WO-2005011601 Feb 2005 WO
WO-2005023806 Mar 2005 WO
WO-2005025504 Mar 2005 WO
WO-2005028480 Mar 2005 WO
WO-2005039564 May 2005 WO
WO-2005051301 Jun 2005 WO
WO-2005060958 Jul 2005 WO
WO-2005063296 Jul 2005 WO
WO-2005097129 Oct 2005 WO
WO-2005100334 Oct 2005 WO
WO-2005117890 Dec 2005 WO
WO-2006032631 Mar 2006 WO
WO-2006062981 Jun 2006 WO
WO-2006065842 Jun 2006 WO
WO-2006074428 Jul 2006 WO
WO-2006082001 Aug 2006 WO
WO-2006092731 Sep 2006 WO
WO-2006109085 Oct 2006 WO
WO-2007007054 Jan 2007 WO
WO-2007022280 Feb 2007 WO
WO-2007036733 Apr 2007 WO
WO-2007036734 Apr 2007 WO
WO-2007050124 May 2007 WO
WO-2007084451 Jul 2007 WO
WO-2007084455 Jul 2007 WO
WO-2007084815 Jul 2007 WO
WO-2007087231 Aug 2007 WO
WO-2007097931 Aug 2007 WO
WO-2007101224 Sep 2007 WO
WO-2007107545 Sep 2007 WO
WO-2007109596 Sep 2007 WO
WO-2007131982 Nov 2007 WO
WO-2008006479 Jan 2008 WO
WO-2008010964 Jan 2008 WO
WO-2008013963 Jan 2008 WO
WO-2008044027 Apr 2008 WO
WO-2008044029 Apr 2008 WO
WO-2008044041 Apr 2008 WO
WO-2008044045 Apr 2008 WO
WO-2008044054 Apr 2008 WO
WO-2008048991 Apr 2008 WO
WO-2008073865 Jun 2008 WO
WO-2008083070 Jul 2008 WO
WO-2008086161 Jul 2008 WO
WO-2008132155 Nov 2008 WO
WO-2008135524 Nov 2008 WO
WO-2008135526 Nov 2008 WO
WO-2008149163 Dec 2008 WO
WO-2009004496 Jan 2009 WO
WO-2009013299 Jan 2009 WO
WO-2009026248 Feb 2009 WO
WO-2009049154 Apr 2009 WO
WO-2009050228 Apr 2009 WO
WO-2009052319 Apr 2009 WO
WO-2009052320 Apr 2009 WO
WO-2009068463 Jun 2009 WO
WO-2009073788 Jun 2009 WO
WO-2009083526 Jul 2009 WO
WO-2009097972 Aug 2009 WO
WO-2009112445 Sep 2009 WO
WO-2009112678 Sep 2009 WO
WO-2009112826 Sep 2009 WO
WO-2009112839 Sep 2009 WO
WO-2009124755 Oct 2009 WO
WO-2009131926 Oct 2009 WO
WO-2009144450 Dec 2009 WO
WO-2010003022 Jan 2010 WO
WO-2010021878 Feb 2010 WO
WO-2010033350 Mar 2010 WO
WO-2010056194 May 2010 WO
WO-2010056195 May 2010 WO
WO-2010077680 Jul 2010 WO
WO-2010086311 Aug 2010 WO
WO-2011078143 Jun 2011 WO
WO-2011090473 Jul 2011 WO
WO-2011094545 Aug 2011 WO
WO-2011107248 Sep 2011 WO
WO-2011140936 Nov 2011 WO
WO-2011146358 Nov 2011 WO
WO-2011159297 Dec 2011 WO
WO-2012019015 Feb 2012 WO
WO-2012027965 Mar 2012 WO
WO-2012028100 Mar 2012 WO
WO-2012031197 Mar 2012 WO
WO-2012043505 Apr 2012 WO
WO-2012062462 May 2012 WO
WO-2012064744 May 2012 WO
WO-2012100732 Aug 2012 WO
WO-2012100734 Aug 2012 WO
WO-2012106995 Aug 2012 WO
WO-2012125521 Sep 2012 WO
WO-2012136296 Oct 2012 WO
WO-2012139775 Oct 2012 WO
WO-2013000994 Jan 2013 WO
WO-2013019621 Feb 2013 WO
WO-2013019626 Feb 2013 WO
WO-2013019635 Feb 2013 WO
WO-2013019653 Feb 2013 WO
WO-2013019682 Feb 2013 WO
WO-2013029338 Mar 2013 WO
WO-2013045431 Apr 2013 WO
WO-2013064231 May 2013 WO
WO-2013067036 May 2013 WO
WO-2013078233 May 2013 WO
WO-2013078240 May 2013 WO
WO-2013079223 Jun 2013 WO
WO-2013083741 Jun 2013 WO
WO-2013087739 Jun 2013 WO
WO-2013092460 Jun 2013 WO
WO-2013092939 Jun 2013 WO
WO-2013092941 Jun 2013 WO
WO-2013096496 Jun 2013 WO
WO-2013100027 Jul 2013 WO
WO-2013159095 Oct 2013 WO
WO-2013160418 Oct 2013 WO
WO-2013160419 Oct 2013 WO
WO-2013166013 Nov 2013 WO
WO-2013169588 Nov 2013 WO
WO-2013169704 Nov 2013 WO
WO-2013169864 Nov 2013 WO
WO-2013171729 Nov 2013 WO
WO-2013178362 Dec 2013 WO
WO-2014008214 Jan 2014 WO
WO-2014009447 Jan 2014 WO
WO-2014026327 Feb 2014 WO
WO-2014026328 Feb 2014 WO
WO-2014026329 Feb 2014 WO
WO-2014026330 Feb 2014 WO
WO-2014028589 Feb 2014 WO
WO-2014028591 Feb 2014 WO
WO-2014028597 Feb 2014 WO
WO-2014028600 Feb 2014 WO
WO-2014028669 Feb 2014 WO
WO-2014044738 Mar 2014 WO
WO-2014062938 Apr 2014 WO
WO-2014086894 Jun 2014 WO
2014110442 Jul 2014 WO
WO-2014179564 Nov 2014 WO
WO-2015038503 Mar 2015 WO
WO-2015083130 Jun 2015 WO
WO-2015100420 Jul 2015 WO
WO-2015101928 Jul 2015 WO
WO-2015114157 Aug 2015 WO
WO-2015116904 Aug 2015 WO
WO-2015144480 Oct 2015 WO
WO-2015144605 Oct 2015 WO
WO-2015144609 Oct 2015 WO
WO-2015144803 Oct 2015 WO
WO-2015159233 Oct 2015 WO
WO-2016061160 Apr 2016 WO
WO-2016064970 Apr 2016 WO
WO-2016144351 Sep 2016 WO
WO-2017024018 Feb 2017 WO
WO-2017087608 May 2017 WO
WO-2017132432 Aug 2017 WO
Non-Patent Literature Citations (50)
Entry
Babu et al., Emerging therapeutic strategies in COPD. Drug Discov Today. Mar. 2015;20(3):371-9.
Bendele et al., Animal models of arthritis: relevance to human disease. Toxicol Pathol. Jan.-Feb. 1999;27(1):134-42.
Bendele, Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. Jun. 2001;1(4):377-85.
Campochiaro, The complexity of animal model generation for complex diseases. JAMA. Feb. 17, 2010;303(7):657-8.
Center for Disease Control, Classification of Diseases and Injuries. ICD-9-CM Tabular List of Diseases (FY03). 748 pages, accessed online Sep. 10, 2015.
Chaichian et al., Targeted Therapies in Systemic Lupus Erythematosus: A State-of-the-Art Review. J Clin Cell Immunol. 2013;56:8 pages.
Chiba, Emerging Therapeutic Strategies in Alzheimer's Disease. InTech, retrieved online at: http://dx.doi.org/10.5772/55293. Chapter 9, pp. 181-225, (2013).
Cyr et al., Recent progress on nuclear receptor RORgamma modulators. Bioorganic & Medicinal Chemistry Letters. 2016;26:4387-4393.
Damia et al., Contemporary pre-clinical development of anticancer agents—What are the optimal preclinical models? European Journal of Cancer. 2009;45:2768-2781.
Edwards et al., Molecular genetics of AMD and current animal models. Angiogenesis. 2007;10(2):119-32.
Elborn, Cystic fibrosis. The Lancet. Retrieved online at: http://dx.doi.org/10.1016/S0140-6736(16)00576-6. 13 pages. Apr. 29, 2016.
Flowers et al., How we treat chronic graft-versus-host disease. Blood. Jan. 22, 2015;125(4):606-15.
Fries et al., O-divinylbenzene and naphthalene. Ber Dtsch Chem Ges B. 1936;69:715-22.
Fries et al., o-Divinylbenzol and Naphtalin. Annalen der Chemie. 1937;533:72-92.
Galiè et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. Oct. 2009;30(20):2493-537.
Hackam et al., Translation of research evidence from animals to humans. JAMA. Oct. 11, 2006;296(14):1731-2.
Healthline, Overview. Retrieved online at: http://www.healthline.com/health/inflammatory-bowel-disease. 7 pages. (2005-2015).
Hynes et al., The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)—A potent and efficacious p38alpha MAP kinase inhibitor. Bioorg Med Chem Lett. Mar. 15, 2008;18(6):1762-7.
Ito et al., A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci. Jan. 2003;94(1):3-8.
Johnson et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. May 18, 2001;84(10):1424-31.
Jordan, Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. Mar. 2003;2(3):205-13.
Lamotte et al., Discovery of novel indazole derivatives as dual angiotensin II antagonists and gartial PPAR? agonists. Bioorg Med Chem Lett. Feb. 15, 2014;24-4):1098-103.
Ledford, US cancer institute to overhaul tumour cell lines. Nature. Feb. 25, 2016;530(7591):391.
Lim et al., Age-related macular degeneration. Lancet. May 5, 2012;379(9827):1728-38.
Lutz et al., Overview of Animal Models of Obesity. Curr Protoc Pharmacol. Sep. 2012 Chapter: Unit 5.61. 22 pages.
Maddur et al., Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. Jul. 2012;181(1):8-1 8.
Makrilakis, Pathophysiology of Type 2 diabetes. Diabetes in Clinical Practice: Questions and Answers from Case Studies. John Wiley & Sons, Ltd. Chapter 3, pp. 43-58, (2006).
Marcoux et al., Annulation of ketones with vinamidinium hexafluorophosphate salts: an efficient preparation of trisubstituted pyridines. Org Lett. Jul. 27, 2000;2(15):2339-41.
Ocana et al., Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol. 2011;8:200-209.
Pilz et al., Modern multiple sclerosis treatment—what is approved, what is on the horizon. Drug Discov Today. Dec. 2008;13(23-24):1013-25.
Quinby, Conventional Therapy. Psoriasis and Psoriatic Arthritism. An Integrated Approach. Kenneth B. Gordon (Ed.), Springer-Verlag, Berlin Heidelberg. Chapter 9, pp. 134-184, (2005).
Sangshetti et al., Antileishmanial drug discovery: comprehensive review of the last 10 years. RSC Adv. 2015;5:32376-32415.
Schlecker et al., Regioselective Metalation of Pyridinylcarbamates and Pyridinecarboxamides with (2,2,6,6-Tetramethylpiperidino)magnesium Chloride. J Org Chem. 1995;60:8414-8416.
Schlecker et al., Regioselective Monometalation of 2,5-Pyridinedicarboxamides with (2,2,6,6-Tetramethylpiperidino)magnesium Chloride (TMPMgCI). Liebigs Ann. 1995;8:1441-1446.
Schonherr et al., Profound Methyl Effects in Drug Discovery and a Call for New C—H Methylation Reactions. Angew Chem Int Ed. 2013;52:12256-67.
Sharma et al., Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. Apr. 2010;10(4):241-53.
Sime et al., Discovery of GSK 1997132B a novel centrally penetrant benzimidazole PPAR? partial agonist. Bioorg Med Chem Lett. Sep. 15, 2011;21(18):5568-72.
STN Registry No. 1030136-78-7, 2H-Indazole-6-carboxamide, 1 page, (2020).
STN Registry No. 1030136-78-7. 2H-Indazole-6-carboxamide, N-[(4-chlorophenyl)methyl]-2-[{4-methoxyphenyl)methyl]. Jun. 24, 2008.
STN Registry No. 1115530-36-3, Thieno[2,3-d]pyrimidine-6-carboxamide, N-[(2-bromophenyl)methyl]-4-(4-ethyl-1-piperazinyl)-5-methyl. Mar. 4, 2009.
STN Registry No. 1141899-39-9, 6-Isoquinolinecarboxamide, N-((2,4- dichlorophenyl)methyl)-1,2,3,4-tetrahydro-2-(4-(methylamino)-6-phenyl-1,3,5-triazine-2-yl). May 1, 2009.
STN Registry No. 1346976-76-8, 2H-Indazole-6-carboxamide, 2-[2-[5-(aminocarbonyl)-1H-pyrazol-1-yl]ethyl]-N-[(3-chlorophenyl)methyl]. Dec. 1, 2011.
STN Registry No. 926926-48-9, 6-Isoquinolinecarboxamide, N-(cyclopropylmethyl)-2-(6,7-dimethoxy-4-quinazolinyl)-1,2,3,4-tetrahydro. Mar. 18, 2007.
University of Cambridge, Alzheimer's disease and tauopathy. John van Geest Centre for Brain Repair, School of Clinical Medicine. 1 page, (2016).
Vickers et al., The utility of animal models to evaluate novel anti-obesity agents. Br J Pharmacol. Oct. 2011;164(4):1248-62.
Vourloumis et al., Solid-phase synthesis of benzimidazole libraries biased for RNA targets. Tetrahedron Letters. 2003;44:2807-2811.
Wang et al., Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J Med Chem. Jun. 23, 2016;59(12):5911-6.
Yan et al., Quality control in combinatorial chemistry: determination of the quantity, purity, and quantitative purity of compounds in combinatorial libraries. J Comb Chem. Sep.-Oct. 2003;5(5):547-59.
European Office Action for Application No. 16816023.2, dated Jun. 27, 2019, 6 pages.
Copending U.S. Appl. No. 16/751,739, filed Jan. 24, 2020.
Related Publications (1)
Number Date Country
20200148677 A1 May 2020 US
Provisional Applications (1)
Number Date Country
62536114 Jul 2017 US